Lidocaine Infusion in Hystroscopy

NCT ID: NCT03825016

Last Updated: 2020-01-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-01

Study Completion Date

2020-01-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lidocaine infusion in hystroscopic media versus oral diclofenac

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lidocaine

Lidocaine Hydrochloride

Group Type EXPERIMENTAL

Lidocaine Hydrochloride

Intervention Type DRUG

Lidocaine infusion on hystroscopic media during office hystroscopy

Diclofenac

Oral Diclofenac

Group Type EXPERIMENTAL

Diclofenac Sodium

Intervention Type DRUG

Oral Diclofenac Sodium

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lidocaine Hydrochloride

Lidocaine infusion on hystroscopic media during office hystroscopy

Intervention Type DRUG

Diclofenac Sodium

Oral Diclofenac Sodium

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-35 years
* BMI 18.5-30 kg/m2
* Diagnostic hystroscope

Exclusion Criteria

* Previous cervical surgery
* Cervical stenosis
* PID
* allergy to NSAID
* Gastritis or peptic ulcer
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ain Shams University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mohamed S Sweed, MD

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ain Shams University Maternity Hospital

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AS1855

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Intracervical Block During Laminaria Insertion
NCT06478316 NOT_YET_RECRUITING NA
Magnesium and Cramping
NCT06745388 RECRUITING PHASE4